No specific alterations in cancer genes were associated with PD-1 positive tumors, suggesting that the PD-1 positive immune microenvironment in trastuzumab-treated HER2+ tumors might not be correlated with specific gene mutations, at least not to one single recurrent mutation. This evidence concerns the gene ERBB2 and cancer.